SAB Bio raises $175M in oversubscribed private placement; Sanofi participates; cash runway into mid-2028

SAB Biotherapeutics, Inc.

Gross proceeds of $175M from sale of Series B convertible preferred stock and warrants; conversion price $1.75 per common share.
Investors include strategic partner Sanofi, RA Capital, Commodore Capital, Vivo Capital, Blackstone Multi-Asset, and others.
Proceeds to fully fund Phase 2b SAFEGUARD study of SAB-142 in Stage 3 T1D and extend cash runway into middle of 2028.
Warrants exercisable for up to 1.5M additional preferred shares, potentially yielding additional $284M in gross proceeds.
Company received FDA alignment on Phase 2b SAFEGUARD trial design during a Type B meeting on May 29, 2025.

item 1.01 item 3.02 item 8.01 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

SAB Biotherapeutics, Inc.: Filed Certificate of Designations creating Series B Convertible Preferred Stock (effective 2025-07-21).

Change: charter amendment
Effective: 2025-07-21

Exact text from the filing

Pursuant to the terms of the Securities Purchase Agreement, on July 21, 2025, the Company filed the Certificate of Designations with the Delaware Secretary of State designating 2,811,429 shares of its authorized and unissued preferred stock as Series B Convertible Preferred Stock.

View on SEC.gov

Browse all governance changes →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-097078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.